According to the most recent analysis by Emergen Research, the market for obstetrics and gynaecology medicines was valued at USD 13,089.39 million in 2021 and is projected to grow at a revenue CAGR of 7.5% during the forecast period. A significant driver anticipated to promote market revenue growth between 2021 and 2030 is the increased prevalence of menopausal illnesses, Polycystic Ovary Syndrome (PCOS), and other diseases leading to rising need for obstetrics and gynaecology medications.
Hormonal therapy and non-hormonal therapy are the two main therapeutic subtypes used in gynaecological medications. In order to delay or stop the growth of cancer cells, which depend on hormones for growth, hormone therapy adds, blocks, or removes certain hormones from the body. Anti-infective, anti-inflammatory, lubricants, moistures, antidepressants, gabapentin, clonidine, and other medications are used in non-hormonal therapy. Gynecology medications are sold in hospital pharmacies, retail pharmacies, and internet pharmacies for conditions such polycystic ovarian syndrome, menopausal disorders, contraception, and others.
The Business Research Company recently released a number of new reports, including one on the gynaecology drugs market. These reports include statistics on the market for gynaecology drugs, such as the size of the global market for gynaecology drugs, regional market shares, competitors with a gynaecology drugs market share, in-depth market segments for gynaecology drugs, market trends and opportunities, and any other information you might need to succeed in the This market research study on gynaecological medications provides a comprehensive view of everything you require, together with a detailed analysis of the existing and future state of the sector.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.emergenresearch.com/request-sample/1389
Some Key Highlights From the Report
In the market for obstetrics and gynaecology medicines, the non-hormonal therapy category is anticipated to grow at a high revenue CAGR during the forecast period. Any method of birth control that uses other preventative measures rather than interfering with the body’s natural hormonal processes is referred to as non-hormonal. Paroxetine (found in Paxil and other SSRIs), a drug also used to treat depression, is the only non-hormonal medication approved by the Food and Drug Administration to treat hot flashes. Other comparable antidepressants, such as SSRIs like fluoxetine (Prozac), and norepinephrine reuptake inhibitors like venlafaxine (Effexor), have also been shown to be unsuccessful in treating hot flashes.
The postmenopausal disorders application sector is anticipated to generate the biggest revenue share during the projection period. The recommended treatment for menopause-related symptoms as well as for long-term biological changes, like bone loss, brought on by a woman’s body’s declining levels of natural hormones progesterone and oestrogen is postmenopausal hormone therapy, also known as postmenopausal disorders hormone therapy and hormone replacement therapy. Vasomotor instability, a hypothalamic-mediated condition that affects 60% of postmenopausal women and results in hot flashes (also known as hot flushes), sweating, and palpitations, is the menopause symptom that occurs most commonly. By having meals high in calcium and vitamin D or by taking dietary supplements containing these nutrients, osteoporosis can be prevented. Additionally, randomised trials have shown that FDA-approved drugs like alendronate (Fosamax), raloxifene (Evista), and risedronate (Actonel) help halt bone loss.
Over the course of the forecast period, the Europe region is anticipated to have a significantly stable rate of revenue growth in the worldwide obstetrics & gynaecology medicines market. This region includes the following nations: Germany, France, the United Kingdom, Spain, Italy, and the rest of Europe. The market’s revenue growth is primarily being driven by rising awareness regarding the diagnosis and treatment of menstruation diseases as well as rising rates of infections associated with pregnancy. Over 90% of women receive antenatal care for the duration of their pregnancies, according to a regional scientific study by the European Board and College of Obstetrics and Gynecology (EBCOG). In 2021, there were more than 4 million live births in the European Union, with Germany and France leading the way with more than 795,000 and 738,000 births, respectively. Additionally, the number of obstetricians and gynaecologists working in these nations has significantly increased over time. This is anticipated to lead to an increase in patient use of obstetrics and gynaecology medications in hospitals and at home, which will fuel market growth in Europe over the forecast period.
Major companies in the market report include Pfizer Inc., AbbVie Inc., TherapeuticsMD, Inc., Amgen Inc., Johnson & Johnson, Ferring B.V., Lupin, Merck KGaA, Novartis AG, GlaxoSmithKline plc. Abbott, and Eli Lilly and Company, among others.
View the Full Report Description, the Research Methodology, the Content Table, and the Infographics @ https://www.emergenresearch.com/industry-report/obstetrics-and-gynecology-drugs-market
Emergen Research has segmented global the obstetrics and gynecology drugs based on therapeutics, application, distribution channel, and region:
- Therapeutics Outlook (Revenue, USD Million; 2019–2030)
- Hormonal Therapy
- Estrogen Therapy
- Progestin Therapy
- Combination Therapy
- Thyroid Replacement Therapy
- Parathyroid Hormone Therapy
- Non-hormonal Therapy
- Anti-Infective Agents
- Anti-Neoplastic Agents
- Anti-Inflammatory Agents
- Hormonal Therapy
- Application Outlook (Revenue, USD Million; 2019–2030)
- Gynecology Infections
- Female Infertility
- Postmenopausal Disorders
- Polycystic Ovary Syndrome
- Gynecological Cancers
- Distribution Channel Outlook (Revenue, USD Million; 2019–2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Million; 2019–2030)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- Rest of Middle East & Africa
- North America
Significant Advantages for Stakeholders
In order to pinpoint the most lucrative gynaecological cancer medications market prospects, this study offers a comprehensive analysis of the market segments, current trends, projections, and dynamics from 2020 to 2030.
In addition to the market research, important drivers, restraints, and opportunities are also covered.
The power of buyers and suppliers to help stakeholders make profit-driven business decisions and expand their supplier-buyer network is highlighted by Porter’s five forces analysis.
A thorough research of the market segmentation for gynaecological cancer medications helps to identify the current market opportunities.
According to their contribution to worldwide market revenue, the major nations in each area are mapped.
Market player positioning makes benchmarking easier and gives a clear picture of where each business currently stands in the market.
The research analyses market trends, top players, market segments, application areas, and market growth strategies for gynaecological cancer medications on a regional and global scale.
Emergen Research Has a Limited-Time Discount Available (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1389
View Additional Reports by Emergen Research:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
Visit for More Insights: https://www.emergenresearch.com/insights